Dr. Pant on the Third-Line Setting for Metastatic CRC

Shubham Pant, MD
Published: Tuesday, Dec 05, 2017



Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the third-line setting for patients with metastatic colorectal cancer (CRC).

According to Pant, there are not many options for patients with CRC in the third-line setting. Currently, regorafenib (Stivarga) and TAS-102 are the only options for this setting.

Next-generation sequencing is important to determine targets for treatment, explains Pant.
 


Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the third-line setting for patients with metastatic colorectal cancer (CRC).

According to Pant, there are not many options for patients with CRC in the third-line setting. Currently, regorafenib (Stivarga) and TAS-102 are the only options for this setting.

Next-generation sequencing is important to determine targets for treatment, explains Pant.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x